Real‑world effectiveness of first‑line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: analysis from the TTD-RETUD registry
Grupo TTD > Comunicaciones > Real‑world effectiveness of first‑line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: analysis from the TTD-RETUD registry
